title: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
abstract: Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Available screening and diagnostic methods are insufficient to identify the victims before the event occurs. The recognition of the role of the vulnerable plaque has opened new avenues of opportunity in the field of cardiovascular medicine. This consensus document concludes the following. (1) Rupture-prone plaques are not the only vulnerable plaques. All types of atherosclerotic plaques with high likelihood of thrombotic complications and rapid progression should be considered as vulnerable plaques. We propose a classification for clinical as well as pathological evaluation of vulnerable plaques. (2) Vulnerable plaques are not the only culprit factors for the development of acute coronary syndromes, myocardial infarction, and sudden cardiac death. Vulnerable blood (prone to thrombosis) and vulnerable myocardium (prone to fatal arrhythmia) play an important role in the outcome. Therefore, the term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future. (3) A quantitative method for cumulative risk assessment of vulnerable patients needs to be developed that may include variables based on plaque, blood, and myocardial vulnerability. In Part I of this consensus document, we cover the new definition of vulnerable plaque and its relationship with vulnerable patients. Part II of this consensus document will focus on vulnerable blood and vulnerable myocardium and provide an outline of overall risk assessment of vulnerable patients. Parts I and II are meant to provide a general consensus and overviews the new field of vulnerable patient. Recently developed assays (eg, C-reactive protein), imaging techniques (eg, CT and MRI), noninvasive electrophysiological tests (for vulnerable myocardium), and emerging catheters (to localize and characterize vulnerable plaque) in combination with future genomic and proteomic techniques will guide us in the search for vulnerable patients. It will also lead to the development and deployment of new therapies and ultimately to reduce the incidence of acute coronary syndromes and sudden cardiac death. We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients.
authors.affiliation: The Center for Vulnerable Plaque Research, University of Texas-Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA. mn@vp.org
authors.forename: Morteza
authors.initials: M
authors.lastname: Naghavi
authors.forename: Peter
authors.initials: P
authors.lastname: Libby
authors.forename: Erling
authors.initials: E
authors.lastname: Falk
authors.forename: S Ward
authors.initials: SW
authors.lastname: Casscells
authors.forename: Silvio
authors.initials: S
authors.lastname: Litovsky
authors.forename: John
authors.initials: J
authors.lastname: Rumberger
authors.forename: Juan Jose
authors.initials: JJ
authors.lastname: Badimon
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
authors.forename: Pedro
authors.initials: P
authors.lastname: Moreno
authors.forename: Gerard
authors.initials: G
authors.lastname: Pasterkamp
authors.forename: Zahi
authors.initials: Z
authors.lastname: Fayad
authors.forename: Peter H
authors.initials: PH
authors.lastname: Stone
authors.forename: Sergio
authors.initials: S
authors.lastname: Waxman
authors.forename: Paolo
authors.initials: P
authors.lastname: Raggi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Madjid
authors.forename: Alireza
authors.initials: A
authors.lastname: Zarrabi
authors.forename: Allen
authors.initials: A
authors.lastname: Burke
authors.forename: Chun
authors.initials: C
authors.lastname: Yuan
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fitzgerald
authors.forename: David S
authors.initials: DS
authors.lastname: Siscovick
authors.forename: Chris L
authors.initials: CL
authors.lastname: de Korte
authors.forename: Masanori
authors.initials: M
authors.lastname: Aikawa
authors.forename: K E Juhani
authors.initials: KE
authors.lastname: Airaksinen
authors.forename: Gerd
authors.initials: G
authors.lastname: Assmann
authors.forename: Christoph R
authors.initials: CR
authors.lastname: Becker
authors.forename: James H
authors.initials: JH
authors.lastname: Chesebro
authors.forename: Andrew
authors.initials: A
authors.lastname: Farb
authors.forename: Zorina S
authors.initials: ZS
authors.lastname: Galis
authors.forename: Chris
authors.initials: C
authors.lastname: Jackson
authors.forename: Ik-Kyung
authors.initials: IK
authors.lastname: Jang
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
authors.forename: Robert A
authors.initials: RA
authors.lastname: Lodder
authors.forename: Keith
authors.initials: K
authors.lastname: March
authors.forename: Jasenka
authors.initials: J
authors.lastname: Demirovic
authors.forename: Mohamad
authors.initials: M
authors.lastname: Navab
authors.forename: Silvia G
authors.initials: SG
authors.lastname: Priori
authors.forename: Mark D
authors.initials: MD
authors.lastname: Rekhter
authors.forename: Raymond
authors.initials: R
authors.lastname: Bahr
authors.forename: Scott M
authors.initials: SM
authors.lastname: Grundy
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Eric
authors.initials: E
authors.lastname: Boerwinkle
authors.forename: Christie
authors.initials: C
authors.lastname: Ballantyne
authors.forename: William
authors.initials: W
authors.lastname: Insull
authors.forename: Robert S
authors.initials: RS
authors.lastname: Schwartz
authors.forename: Robert
authors.initials: R
authors.lastname: Vogel
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Goran K
authors.initials: GK
authors.lastname: Hansson
authors.forename: David P
authors.initials: DP
authors.lastname: Faxon
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
authors.forename: Helmut
authors.initials: H
authors.lastname: Drexler
authors.forename: Philip
authors.initials: P
authors.lastname: Greenland
authors.forename: James E
authors.initials: JE
authors.lastname: Muller
authors.forename: Renu
authors.initials: R
authors.lastname: Virmani
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
authors.forename: Douglas P
authors.initials: DP
authors.lastname: Zipes
authors.forename: Prediman K
authors.initials: PK
authors.lastname: Shah
authors.forename: James T
authors.initials: JT
authors.lastname: Willerson
mesh_terms: D000818:Animals; D015415:Biomarkers; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000453:epidemiology*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D009206:Myocardium / Q000473:pathology; D018570:Risk Assessment / Q000458:organization & administration*; D012720:Severity of Illness Index; D013552:Swine; D019851:Thrombophilia / Q000097:blood / Q000150:complications / Q000235:genetics
chemical_list: D015415:Biomarkers